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Abstract:  This  study  explored the effect  of  glatiramer  acetate  (GA, 20 mg) on lesion 
activity using the 1.5 T standard MRI protocol (single dose gadolinium [Gd] and 5-min 
delay) or optimized 3 T protocol (triple dose of Gd, 20-min delay and application of an  
off-resonance saturated magnetization transfer pulse). A 15-month, phase IV, open-label, 
single-blinded, prospective, observational study included 12 patients with relapsing-remitting 
multiple  sclerosis  who  underwent  serial  MRI  scans  (Days  −45,  −20,  0;  the  minus  ign 
indicates the number of days before GA treatment; and on Days 30, 60, 90, 120, 150, 180, 
270 and 360 during GA treatment) on 1.5 T and 3 T protocols. Cumulative number and 
volume of Gd enhancing (Gd-E) and T2 lesions were calculated. At Days −45 and 0, there 
were higher number (p < 0.01) and volume (p < 0.05) of Gd-E lesions on 3 T optimized 
compared  to  1.5  T  standard  protocol.  However,  at  180  and  360 days  of the study, no 
significant differences in total and cumulative number of new Gd-E and T 2 lesions were 
found between the two protocols. Compared to pre-treatment period, at Days 180 and 360 
a significantly greater decrease in the cumulative number of Gd-E lesions (p = 0.03 and 
0.021, respectively) was found using the 3 T vs. the 1.5 T protocol (p = NS for both time 
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points).  This  MRI  mechanistic  study  suggests  that  GA  may  exert  a  greater  effect  on 
decreasing lesion activity as measured on 3 T optimized compared to 1.5 T standard protocol.  
Keywords: glatiramer acetate; gadolinium-enhancing lesions; magnetic resonance imaging; 
1.5 T; 3 T; T2 lesions; pilot trial 
 
1. Introduction 
Gadolinium  (Gd)  enhancement  in  multiple  sclerosis  (MS)  lesions  correlates  with  histopathologic 
findings of blood-brain barrier (BBB) breakdown and active inflammation. [1–4] Gd-enhancing (Gd-E) 
lesions on post-contrast T 1-weighted images (WI) usually correspond to areas of high signal intensity 
on T2-WI and low signal intensity on unenhanced T1-WI, probably due to edema and demyelination [5]. 
Gd-enhancement is a transient phenomenon in MS that usually disappears after several weeks [6]. The 
presence of continuing enhancement indicates a higher risk of relapses over the short-to-intermediate 
term and may contribute to long term clinical dysfunction [5]. Various strategies have been proposed 
to increase the sensitivity of Gd-enhanced MRI for the detection of active MS lesions. These strategies, 
which  maximize  the  information  that  can  be  obtained  by  Gd-enhancement,  include  [2]:  
(1) frequent serial monthly scanning; (2) a delay longer than 5 min between Gd injection and scanning; 
(3) using doses of higher contrast (e.g., a double or triple dose instead of a standard 0.1 mmoL/kg dose); 
(4) acquiring thinner tomographic slices; (5) coregistration; (6) reducing the background signal by the 
application of off-resonance saturation magnetization transfer (MT) pulses to T1-WI and (7) use of 
high-field strength scanners [7–9].  
A number of studies used the standard protocol at 1.5 T (a single dose of Gd, with a 5-min scanning 
time delay after Gd injection) to compare with the optimized protocols at 1.5 T or 3 T (a triple dose of 
Gd, with a 20-min scanning time delay after Gd injection, and applied an off-resonance saturated 
magnetization transfer [MT] pulse) [7,10–13]. These investigations confirmed that use of optimized 
protocols and/or stronger field strength scanners may increase the ability to detect Gd-E lesions in 
patients with MS [7–11,13,14]. Gd-E lesions visualized after application of a triple dose of Gd are 
characterized  by  a  smaller  increase  in  BBB  permeability  and  milder  tissue  damage  than  those 
enhancing after a single dose [2].  
Interferon-beta  (IFN-β)  treatment  has  a  robust  effect  on  visible  inflammation  with  the  1.5  T 
standard protocol (when BBB is largely disrupted). This is one of the principal reasons why a decrease 
of >80% is observed in macroscopically visible Gd-E lesions with IFN-β treatment [15]. A previous 
study  showed  that  IFN-β-1a  subcutaneously  (S.C.)  (44  µg)  had  a  significantly  greater  effect  on 
reducing the number of Gd-E lesions visible with a triple dose of Gd than on reducing the number of 
Gd-E lesions visible with a single dose of Gd on the 1.5 T scanner [16]. Another study found that, 
compared to the effect of IFN-β-1a S.C. (44 µg) given once a week, the decrease in the appearance rate 
of new Gd-E enhancing lesions was better with a triple dose of Gd than with a single dose of Gd using 
a 1.5 T scanner [17]. These findings fit with the concept that IFN-β affects the BBB permeability in 
situ, either directly or by decreasing the release of proinflammatory cytokines [18]. On the other hand, 
a study using single and triple doses of Gd on 1.5 T scanner in MS patients treated with glatiramer Int. J. Mol. Sci. 2012, 13  5661 
 
acetate  (GA)  S.C.  (20  mg)  showed  that  GA  reduced  equally  the  mean  numbers  of  Gd-E  lesions 
evidenced on both single and triple doses of Gd, without interaction with the dose of Gd [19]. 
More recently, in the BECOME (Betaseron vs. Copaxone in MS with Triple-Dose Gadolinium and 
3-T MRI Endpoints) study, the effect of IFN-β-1b and GA on new active lesions was tested on the 3 T 
optimized protocol (3 T MRI scanner, a triple dose of Gd, with a 20-min scanning time delay after Gd 
injection) in 75 patients with relapsing-remitting (RR) MS who underwent serial monthly MRI scans 
over 12 months [20]. No differences in treatment effect on new active or Gd-E lesions were seen 
between the two treatment arms. However, in two larger head-to-head studies that evaluated clinical 
and MRI differences between GA and high-dose IFN-β on standard 1.5 T MRI with a single dose of 
Gd,  advantages  in  suppressing  Gd-E  lesions  were  observed  with  high-dose  IFN-β  [21,22].  In  the 
REGARD (Rebif vs. Glatiramer Acetate in Relapsing MS Disease) study, MS patients treated with 
IFNβ-1a S.C. (44 µ g) had significantly fewer Gd-E lesions (0.24 vs. 0.41 per patient per scan, p = 0.0002), 
than those treated with GA [21]. In the BEYOND (Betaferon/Betaseron Efficacy Yielding Outcomes 
of a New Dose in Multiple Sclerosis [MS] Patients) study, which compared 2 doses of IFNβ-1b S.C. 
(250  µg  or  500  µg)  with  20  mg  GA  daily  in  2244  patients,  the  cumulative  volume,  but  not  the 
cumulative  number,  of  Gd-E  lesions  from  baseline  to  last  available  scan  was  significantly  lower  
(p = 0.028) for 500 μg IFNβ-1b (non-marketed dose) compared with GA [22]. All in all, data from these 
recent head-to head trials that used 3 T optimized and 1.5 T standard protocols suggest that GA may 
favorably affect early events in lesion formation (smaller lesions visible only on 3 T optimized protocol), 
in  addition  to  exerting  more  transient  beneficial  effects  on  established  areas  of  inflammation  and 
demyelination (larger lesions visible on 1.5 T standard protocol). Furthermore, GA may have a more 
diffuse,  less  focal  action  in  the  brain.  This  action  can  be  recognized  only  on  the  3  T  optimized  
protocol [23]. 
Based on  this  background, we hypothesized that use of the 3 T optimized compared to 1.5  T 
standard protocol may shed light on GA’s mechanism of action. Therefore, the aim of this pilot study 
was to investigate mechanisms by which GA influences inflammation in MS as evidenced by serial 
MRIs. Specifically, the present study had 2 objectives: (1) to explore whether the 3 T optimized vs. the 
1.5 T standard protocol provides stronger evidence that GA decreases inflammation as shown by a 
decrease in  the cumulative number of Gd-E lesions  over 180 and 360 treatment  days,  and  (2) to 
compare  whether  the  decrease  in  the  cumulative  number  of  Gd-E  lesions  significantly  differs  
between pre-treatment and post-treatment (180 and 360 days) periods using 1.5 T standard and 3 T  
optimized protocols. 
2. Results 
Of the 12 RRMS patients enrolled, 8 patients completed the 180- and 360-day clinical and MRI 
follow-up. Of the remaining 4 patients, 1 dropped out at Day 60 due to pregnancy; 1 left the study at 
Day 90 due to implantation of a metal device incompatible with MRI scanning; 1 dropped out at Day 
120 due to an inability to adhere to the MRI schedule; and 1 discontinued the study at Day 150 due  
to incarceration.  
The  clinical  characteristics  of  all  enrolled  patients  (Day  −45)  and  those  who  completed  MRI 
assessments at Days 180 and 360 (completers) are provided in Table 1. There were no statistically Int. J. Mol. Sci. 2012, 13  5662 
 
significant  differences  for  clinical  and  demographic  characteristics  between  enrolled  patients  
and completers. 
Table 1. Demographic and clinical characteristics of enrolled patients and those completing the study. 
Clinical Characteristics  Enrolled Patients 
(N = 12) 
Completers 
(n = 8) 
% Female  75  83.3 
Age (y), mean (SD)   43 (7.8)  43.1 (7.7) 
Age onset (y), mean (SD)   31.3 (10.4)  31.2 (10.1) 
Disease duration (y), mean (SD)   12.8 (7.9)  12.6 (7.8) 
Relapses in 1 year before study entry, mean (SD)   0.92 (0.99)  0.9 (0.8) 
Number of relapses in 1 year before study entry, n (%) 
0 
1 
2 
3 
 
5 (41.6) 
4 (33.3) 
2 (16.6) 
1 (8.3) 
 
4 (50) 
2 (25) 
1 (12.5) 
1 (12.5) 
EDSS, mean (SD) median   2.7 (1.1) 2.5  2.8 (0.8) 2.5 
Legend:  SD  =  standard  deviation;  EDSS  =  Expanded  Disability  Status  Scale.  There  were  no 
statistically significant differences between patients enrolled in the study and the study completers 
for baseline clinical and demographic characteristics. Patients who stopped the study drug were 
asked to remain in the study and were analyzed with the intention-to-treat, but adding a covariate 
for the month of the drop-out. 
In terms of clinical results, 7 relapses occurred during the year prior to study treatment initiation 
and 4 of those were recorded in the pre-treatment period; 6 relapses occurred during the 180 treatment 
period; no relapses occurred in 180–360 treatment period. All relapses were treated with 1 g MP by IV 
infusion daily for 3–5 days. Overall, 3 (25%) of the 12 patients presented with a relapse during the 
treatment period. EDSS scores remained stable, albeit slightly improved, during the 180 and 360 days 
of treatment, with mean scores of 2.8 ±  0.8 and 2.7 ±  0.6, respectively. No serious adverse events (AEs) 
were recorded. Patients showed the usual AEs as indicated in the package insert for GA, but AEs were 
not systematically recorded.  
MRI characteristics prior to GA treatment at Days −45 and Day 0 for the 1.5 T standard and 3 T 
optimized protocols are shown in Table 2. The mean number of Gd-E lesions was significantly lower 
using the 1.5 T vs. 3 T protocol at Day −45 (p = 0.01) and Day 0 (p = 0.0006). The mean Gd-E lesion 
volume at Day −45 and Day 0 using the 1.5 T was significantly lower than that obtained with the 3 T 
optimized protocol (p < 0.0001 and p = 0.04, respectively). Mean T1 and T2 lesion numbers and 
volumes at Day −45 and Day 0 were also calculated, but differences did not reach statistical significance. 
Table 3 and Figure 1 show the cumulative lesion activity and number of active scans (defined as a 
scan with a Gd-E lesion) evidenced during the pre-treatment period (Days −45 to Day 0), treatment 
period (Days 0–180 and Days 180–360) using the 1.5 T standard and 3 T optimized protocols. There 
was a trend for lower mean cumulative number of Gd-E lesions during pre-treatment using the 1.5 T 
standard versus the 3 T optimized protocol (2.5 ±  2.1 vs. 5.3 ±  5.9; p = 0.065). However, at 180 and  
360 days, there was no difference in the mean cumulative number of Gd-E lesions using the 1.5 T vs. 
the 3 T protocol. Int. J. Mol. Sci. 2012, 13  5663 
 
Table 2. MRI characteristics at Days −45 (i.e., 45 days before treatment started) and Day 0 
on 1.5 T standard and 3 T optimized protocols.  
  Day −45 
1.5 T 
Standard 
Protocol 
(n = 12) 
Day −45 
3 T 
Optimized 
Protocol 
(n = 12) 
p value  Day 0 
1.5 T 
Standard 
Protocol 
(n = 12) 
Day 0 
3 T 
Optimized 
Protocol 
(n = 12) 
p value 
Gd-E number, mean (SD)  
min–max 
2.7 (2.1) 
1–5 
6.2 (4.1) 
1–11 
0.01  0.8 (0.6) 
0–3 
3.1 (1.9) 
1–8 
0.0006 
Gd-E volume, 
† mean (SD)  0.33 (0.07)  0.66 (0.2)  <0.0001  0.1 (0.1)  0.36 (0.4)  0.04 
T2 lesion number, mean 
(SD) min-max 
37 (37.8) 
10–71 
42.6 (24.7) 
26–93 
NS  28.7 (27) 
10–83 
35.1 (21.4) 
12–99 
NS 
T2 LV, mean (SD)  26.1 (38.1)  34.6 (44.6)  NS  22.2 (25.9)  28.8 (29.1)  NS 
T1 lesion number, mean 
(SD) min-max 
11.3 (10) 
26–45 
25 (17) 
44–75 
NS  14.9 (15.4) 
3–49 
21 (15.1) 
4–51 
NS 
T1 LV, mean (SD)  2.4 (3.7)  5.1 (5.6)  NS  2.5 (4.1)  5.8 (5.9)  NS 
Legend:  Gd-E  =  gadolinium-enhancing  lesion;  SD  =  standard  deviation;  LV  =  lesion  volume;  
NS = non-significant. All MS patients at screening presented at least 1 Gd-E lesion on the 1.5 T standard 
protocol. There was a significant difference between 1.5 T standard and 3 T optimized protocols in Gd-E 
number and volume at Days −45 and Day 0. For comparisons, the Student’s t-test and Wilcoxon rank sum 
test were used. 
† The LV results are expressed in milliliters.  
Figure  1.  Differences  in  cumulative  number  of  gadolinium-enhancing  lesions  between  
1.5 T standard and 3 T optimized protocols on serial MRI time points of the study. 
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Table 3. MRI cumulative lesion activity and active scans in the pre-treatment (Days −45 to Day 0) and treatment periods (Days 0–180 and  
0–360) on 1.5 T standard and 3 T optimized protocols. 
  −45 to 0 Days 
1.5 T 
Standard 
Protocol 
(n = 12) 
−45 to 0 Days 
3 T 
Optimized 
Protocol 
(n = 12) 
p value  0–180 Days 
1.5 T 
Standard 
Protocol 
(n = 12) * 
0–180 Days  
3 T 
Optimized 
Protocol 
(n = 12) * 
p value  0–360 Days  
1.5 T 
Standard 
Protocol 
(n = 12) * 
0–360 Days  
3 T 
Optimized 
Protocol 
(n = 12) * 
p value 
Cumulative Gd-E number, 
mean (SD) min-max (sum) 
2.5 (2.1) 
1–4 (5) 
5.3 (5.9)  
1–12 (16) 
0.065  3.5 (4.1)  
1–10 (18) 
3.7 (5.8)  
1–15 (22) 
NS  3.6 (4.2)  
1–11 (20) 
3.8 (5.4)  
1–15 (24) 
NS 
Cumulative T2 lesion 
number, mean (SD)  
min-max (sum) 
1 (1) 
0–1 (2) 
2.5 (2.1) 
1–4 (5) 
NS  3.2 (2.6) 
2–9 (24) 
3.3 (3) 
1–9 (30) 
NS  5 (3.6) 
2–9 (40) 
5 (3.3) 
1–9 (41) 
NS 
Active Gd-E scan per 
patient, number (%) 
6 (50)  9 (75)  NS  4 (33.3)  4 (33.3)  NS  4 (33.3)  4 (33.3)  NS 
Active T2 scan per patient, 
number (%) 
4 (33.3)  6 (50)  NS  3 (25)  3 (25)  NS  3 (25)  3 (25)  NS 
* All available pairs of scans (1.5 T and 3 T) in the pre- and post-treatment periods were used in the analysis. All 12 enrolled patients entered into the intention-to-treat 
(ITT) analysis. Because some data were missing for the post-baseline MRI endpoints, the principle of “last observation carried forward” was used for the value. If no  
post-baseline value was available for a subject, then the mean value was calculated at the specified visit using all available data. The mean value was used as the imputed 
value. Gd-E = gadolinium-enhancing lesion; SD = standard deviation; NS = non-significant; Cumulative number of Gd-E lesions represents sum of all Gd-E lesions at 
serial time points. For comparisons, the chi square test, Student’s t-test and Wilcoxon rank sum test were used, as appropriate. Int. J. Mol. Sci. 2012, 13  5665 
 
During the pre-treatment period, 6 patients (50%) had active Gd-E scans using the 1.5 T standard 
protocol and 9 patients (75%) had active Gd-E scan using the 3  T optimized protocol (p = NS). 
However, at Days 180 and 360 during treatment, the number of patients having active Gd-E scans was 
4 (33.3%) for 1.5 T and 3 T; p = NS. 
During the 180 and 360 treatment periods of the study, there were no differences in the cumulative 
number of new Gd-E and T2 lesions using the 3 T optimized and the 1.5 T standard protocol, although 
there was significantly higher Gd-E lesion activity at Day 0 on the 3 T optimized compared with the  
1.5 T standard protocol (p = 0.0006). Compared to the pre-treatment period, at Days 180 and 360, a 
significantly  greater  decrease  in  the  cumulative  number  of  Gd-E  lesions  (p  =  0.03  and  0.021, 
respectively) was found using the 3 T vs. the 1.5 T protocol (p = NS for both time points).  
The mean cumulative T2 lesion number was approximately half using the 1.5 T standard (1 ±  1) 
compared with the 3 T optimized protocol (2.5 ±  2.1; p = NS) during pre-treatment, but there was a 
similar  cumulative  number  of  T2  lesions  at  Days  180  and  360  during  treatment.  The  number  of 
patients having active T2 scans during pre-treatment was 4 (33.3%) using the 1.5 T standard protocol, 
and 6 (50%) using the 3 T optimized protocol (p = NS). As with the number of active Gd-E scans per 
patient, the number of patients with active T2 scans was non-significant regardless of protocol type 
(1.5 T or 3 T) or time period (180 or 360 days) during treatment (3 patients). 
3. Discussion 
This was a pilot mechanistic study, evaluating the evolution of Gd-E lesions in patients with RRMS 
through serial scans using 1.5 T standard and 3 T optimized protocols. During the 180- and 360-day 
treatment periods, there were no significant differences in the cumulative number of Gd-E and T2 
lesions using the 1.5 T standard vs. the 3 T optimized protocol, although there was significantly higher 
Gd-E lesion activity at Day 0 on the 3 T optimized versus the 1.5 T standard protocol and a trend for 
higher  cumulative  Gd-E  lesion  number  in  the  pre-treatment  period.  When  compared  with  the  
pre-treatment period, there was a significant decrease in the mean cumulative number of Gd-E lesions 
in the treatment period with the 3 T optimized but not with the 1.5 T standard protocol. These MRI 
findings suggest that GA exerted a more beneficial effect on Gd-E on the 3 T optimized compared 
with the 1.5 T standard protocol by probably inhibiting early events in lesion formation. Therefore, GA 
may favorably affect early events in lesion formation, in addition to exerting more transient beneficial 
effects on established areas of inflammation and demyelination.  In other words, GA can exert an 
additional effect on smaller lesions not macroscopically visible on a 1.5 T standard protocol. 
A  single  dose  of  Gd  1.5  T  standard  MRI  provides  only  indirect  information  on  the  degree  of 
inflammation that accompanies active MS lesions, and does not take into account the presence of 
smaller Gd lesions  in  the  normal  appearing  (NA) white matter  (WM)  and  gray matter (GM)  [2]. 
However, Gd lesions enhancing only after a triple dose on 3 T MRI are characterized by a smaller 
increase in BBB permeability and milder tissue damage than those enhancing after a single dose of Gd. 
Therefore,  the  use  of  standard  vs.  optimized  protocols  may  be  appropriate  for  investigating  the 
treatment effect on events responsible for early microscopic pre-enhancing lesion formation in the 
NAWM and NAGM that occur in the absence of or during partial BBB breakdown [24].  Int. J. Mol. Sci. 2012, 13  5666 
 
 
The results from this study confirm results of the previous study by Rovaris et al. [19], which 
examined the effect of GA on MS lesions enhancing at different Gd doses. The data from this study 
revealed that GA significantly reduces the mean numbers of Gd-E lesions per patient per month, using 
standard and triple doses of Gd independent of the severity of the 1.5 T MRI-detectable inflammatory 
process capable of being tracked via different doses of Gd. It was hypothesized that the absence of a 
significant interaction between the Gd dose and treatment efficacy was perhaps due to a homogeneous 
effect of GA on Gd-E lesions that may not be dependent on the severity of BBB disruption [19]. 
Activation  of  blood-borne  effector  mononuclear  cells  that  determine  BBB  disruption  and  Gd 
enhancement is driven primarily by antigen-specific T cells [19]. Rovaris et al., therefore, suggested 
that GA may act via inhibition of antigen-specific T cells rather than directly on effector cells, which 
may be the mechanism by which GA affects early events in lesion formation, in addition to exerting 
more transient beneficial effects on established areas of inflammation and demyelination. Because GA 
was equally effective on single and triple Gd dose 1.5 T scans in the previous study [19] and on 1.5 T 
standard vs. 3 T optimized protocol in the current study, it could be hypothesized that GA can influence 
the  inflammatory  events  responsible  for  early  microscopic  pre-enhancing  lesion  formation  in  the 
NAWM and NAGM that occur in the absence of or during partial BBB breakdown. The effect of GA 
on slowing deterioration with non-conventional MRI measures was previously investigated [23,25,26].  
Although still not fully elucidated, several mechanisms of action (MOA) have been proposed for 
GA (generating suppressor cells,  inducing  tolerance, expanding  regulatory  T-cell populations,  and 
altering antigen-presenting cells) [27]. Contrary to the MOA of IFN-β [28], the anti-inflammatory 
activity of GA does not require a blockade of the BBB; rather, GA-specific T-cells are believed to 
enter the central nervous system to exert anti-inflammatory effects [27,28]. Surrogate biomarkers of 
MS disease activity are being sought to assess the efficacy of various therapeutic interventions in 
individual patients, as well as in clinical trials. Use of 1.5 T standard vs. 3 T optimized protocols offer 
the potential to provide this information.  
The hypothesis that GA administration might inhibit formation of smaller areas of demyelination 
(not visible with either a single or triple dose of Gd on the 1.5 T scanner) has been advanced with the 
results of the BECOME study [20]. There was a similar median (75th percentile) number of combined 
active lesions per patient per scan for months 1–12: 0.63 (2.76) for IFNβ-1b and 0.58 (2.45) for GA  
(p = 0.58). The primary outcome of the study after 12 months did not distinguish between the two 
treatment  arms,  although  patients  on  GA  exhibited  441  Gd-E  lesions  and  patients  on  IFNβ-1b 
developed a total of 913 (472 more than in the GA arm) [20]. The BECOME study’s findings suggest 
that IFN-β and GA may facilitate repair in the majority of new brain lesions. Also, GA may have 
decreased the number of smaller Gd-E lesions visible on the 3 T optimized protocol that were probably 
not  visible  on  the  1.5  T  single-  or  triple-dose  Gd  protocols.  Future  studies  using  emerging  
disease-modifying treatments may benefit from using enhanced MRI protocols.  
This pilot study had potential limitations that may influence interpretation of our findings, such as a 
small study population and absence of a control group. The study was designed as a proof-of-concept 
pilot investigation, to provide sufficient evidence which could justify additional longitudinal studies 
with a larger sample size to examine head-to-head disease-modifying agent differences on standard 
and optimized MRI protocols. Based on the current results, an active control group, to be compared Int. J. Mol. Sci. 2012, 13  5667 
 
 
with GA, is recommended for future studies using a similar study design. The serial monthly MRI 
scanning on both 1.5 T and 3 T MRI scanners (>200 MRI scans in 12 MS patients over 15 months) 
was one of the main limits in successful recruiting of larger sample size of MS patients. However, a 
careful randomization and blinding of the MRI scanner protocols at every time point of the study 
strengthens the validity of our study results. Although the regression to the mean could have affected 
frequency of Gd-E lesions over time, this effect should have been equally distributed between both 
standard and optimized MRI protocols. In addition, the drop-out rate was relatively high in the present 
study; however, those patients who stopped the study drug were asked to remain in the study and were 
included in the ITT analysis, where the month of the drop-out was added to the analyses as a covariate. 
In order to ensure that the presence of limited time points for 4 patients who dropped-out from the 
study did not skew the analyses, the analyses were repeated without including the 4 patients. The 
results  were  similar  to  the  IIT  findings,  and  therefore  it  was  decided  that  the  IIT  results  should  
be presented. 
4. Materials and Methods 
4.1. Patient Population 
The  study  population  included  12  consecutively  enrolled  patients  with  RRMS  who  satisfied 
inclusion and exclusion criteria. Briefly, patients were 18 to 65 years of age, had disease duration of  
3 months  to  20  years,  and were diagnosed with RRMS according  to  the McDonald  criteria  [29]. 
Patients had to have 1 Gd-E lesion within 30 days on a screening scan and/or an acute relapse within  
3 months prior to study screening. Kurtzke Expanded Disability Status Scale (EDSS) scores had to be  
≤5.5 [30]. Although treatment with steroids was allowed for relapses prior to study randomization, 
patients were excluded if they had received immunomodulatory or immunosuppressant treatment (with 
[IFN-β,  GA,  mitoxantrone,  cyclophosphamide,  cladribine,  fludarabine,  cyclosporine,  total  body 
irradiation, azathioprine, methotrexate, intravenous [IV] immunoglobulin, mycophenolate mofetil, or 
natalizumab) during the 30 days prior to Day −45 of the study. Patients were also excluded if they had 
renal disease, due to the potential risk of complications from Gd exposure. 
4.2. Study Design 
This was a 15-month, phase IV, open-label, single-blinded, prospective MRI observational study. 
All patients were GA-naive and received monotherapy with GA (20 mg/day S.C.) every day beginning 
at the baseline visit (Day 0) for 12 months; no special precautions were necessary before using GA. IV 
methylprednisolone (IVMP) was allowed for relapses (1 g MP by IV infusion daily for 3–5 days). 
Patients were permitted to use additional medications, such as antidepressants, for symptom control. 
The  study  was  approved  by  the  local  Institutional  Review  Board  and  all  patients  gave  informed 
consent (Clinicaltrials.gov identifier number: NCT00937157). Int. J. Mol. Sci. 2012, 13  5668 
 
 
4.3. MRI Methods 
4.3.1. MRI Acquisition 
All potential patients underwent a screening scan using the 1.5 T standard protocol (to confirm the 
presence of at least 1 Gd-E lesion). Patients enrolled in the study then received serial MRI scans of the 
brain with the 1.5 T standard and 3 T optimized protocols at Day−45, Day−20, Day 0, Day 30, Day 60, 
Day 90, Day 120, Day 150, Day 180, Day 270, and Day 360. The interval between 1.5 T standard and 
3 T optimized protocols was at least 72 h to avoid effects from the first Gd injection. The scanner order 
of 1.5 T standard versus 3 T optimized protocol was randomized in blocks of 4. The standard T1-WI post-
contrast scan utilized a standard 0.1 mmoL/kg dose of Gd with a 5-min delay, whereas the triple dose 3 
T optimized protocol used a 0.3 mmoL/kg dose of Gd with a 20-min delay and application of an MT 
saturation pulse. All patients underwent MRI scans of the brain on the same 2 scanners: 1.5 T General 
Electric Signa Excite 4x/Lx, Milwaukee, WI, and 3 T General Electric Signa Excite 4x/Lx, Milwaukee, 
WI. The scanning protocol on 1.5 T and 3 T scanners included: axial fast-spin echo proton density 
(FSE) PD/T2, axial spoiled gradient recalled (SPGR), axial pre- and post-contrast T1-WI with and 
without MT pulse, and axial fluid attenuation inversion recovery (FLAIR).  
The standard 1.5 T MRI protocol was applied with a 256 ×  192 matrix and a field of view (FOV) of 
24 cm. Other parameters included the following: the dual FSE PD/T2 sequence was acquired with echo 
time (TE) and repetition time (TR) of TE1/TE2/TR = 10/90/7475 ms, echo train length (ETL) of 12,  
46 slices, 3 mm thick, no gap, 1 average, and an acquisition time (AT) of 4:07 (min:s); axial SE T1 
imaging before and 5 min after contrast injection with TE/TR = 12/450 ms, 46 slices, 3 mm, no gap,  
1 average, AT of 4:27; and FLAIR sequence with TE/TI/TR = 120/2000/8000 ms, (TI-inversion time) 
46 slices, 3 mm thick, no gap, 1 average, AT = 5:21. 
The 3 T optimized MRI protocol was applied with a 256 ×  256 matrix and a FOV of 25.6 cm. Other 
parameters were the following: for the PD/T2 sequence the TE1/TE2/TR = 12/95/3000 ms, ETL = 14, 
47 slices, 3 mm, no gap, 1 average, AT = 4:31; axial SE T1 imaging before and 20 min after contrast 
injection with TE/TR = 9/600 ms, 47 slices, 3 mm, no gap, 1 average, AT = 12:22, an 8 ms Fermi MT 
pulse was used on the 3 T MRI with a 1200 Hz off-resonance frequency to reduce the background 
signal, and FLAIR sequence with TE/TI/TR = 120/2100/8500 ms, 46 slices, 3 mm thick, no gap,  
1 average, AT = 4:16. 
4.3.2. MRI Analysis  
MRI  investigators  were  blinded  to  the  field  strength/protocol  type  and  to  the  patients’  clinical 
characteristics and clinical status.  
The number and lesion volume (LV) of Gd-E, T2, and T1 lesions were calculated using a highly 
reproducible semiautomated technique. [31] Lesion activity analysis included calculation of Gd-E and 
T2  active  lesions  and  active  scans  on  the  1.5  T  standard  and  3  T  optimized  protocols  after 
coregistration of serial time points. Coregistration was performed using the FMRIB’s Linear Image 
Registration Tool (FLIRT) tool [32] to place all scans for a single patient into the same physical space 
as the pre-contrast T1-WI from Day −45. All coregistrations were run using six degrees of freedom, a Int. J. Mol. Sci. 2012, 13  5669 
 
 
correlation ratio cost function, and trilinear interpolation. Although FLIRT is fully automated, the 
results were manually checked by an operator to ensure their accuracy. 
Gd-E lesion was defined as a well demarcated area of unequivocally increased hyperintense signal 
intensity on post-contrast T1-WI compared with surrounding normal-appearing brain tissue (NABT) 
that is not hyperintense on the pre-contrast T1-WI. [33] The hyperintensities were defined as Gd-E 
lesions if the signal increase was not related to a normally enhancing structure (e.g., a vessel or choroid 
plexus) and not identified as a flow-related artifact. Small Gd-E lesions had to be present in more than 
one slice. T2 confirmation was mandatory for difficult areas, such as the posterior fossa (with many flow 
artifacts and confusing tentorial vessels) and the temporal lobes. The mean cumulative number of Gd-E 
lesions per patient over the 45-day pre-treatment and 180- and 360-day treatment period was measured.  
A new or enlarging T2-WI lesion was defined as a rounded or oval lesion arising from an area 
previously considered NABT or a lesion showing an identifiable increase in size from a previous time 
point, respectively. Lesion activity was calculated using a reliable contouring-thresholding technique, 
as previously reported [31,34]. The mean cumulative number of T2 lesions per patient over the 45-day 
pre-treatment and 180- and 360-day treatment period were measured.  
The percentage of active scans showing one or more new enhancing, or new or newly enlarging T2 
lesions was also determined. An active scan was defined as a scan showing any new, enlarging, or 
recurrent lesion on post-contrast T1- and T2-WI.  
4.4. MRI, Clinical, and Safety Time Points 
The serial MRI scans were acquired in the pre-treatment period: screen, Days −45, −20, and 0, and 
during the treatment period: Days 30, 60, 90, 120, 150, 180, 270 and 360, using the relevant 1.5 T 
(standard) and 3 T (optimized) MRI protocols. Three pre-treatment MRI scans were used to calculate 
the baseline level of activity on the 1.5 T standard and 3 T optimized protocols. After treatment with 
GA (20 mg/day S.C.) began (Day 0), patients underwent 6 consecutive monthly MRI scans at Days 30, 
60, 90, 120, 150 and 180. Additional scans were acquired on Day 270 and Day 360, during GA 
treatment. In total, patients had 22 MRI scans during the 15 months of the study. 
The clinical visits occurred at Days −45, 0, 90, 180, 270 and 360, as well as during unscheduled 
relapses. Patients were evaluated based on physical examinations, routine laboratory examinations for 
safety monitoring and pregnancy, as well as neurologic assessments.  
4.5. Endpoints 
The primary endpoint was to determine a decrease in inflammatory activity, as evidenced by a 
decrease in the number of Gd-E lesions with the 3 T optimized and 1.5 T standard protocols in the 
treatment period (Days 180 to 360), when compared with the pre-treatment period (Days −45 to 0). 
The secondary endpoint of the study was to compare the cumulative number of Gd-E lesions acquired 
with the 3 T optimized and 1.5 T standard protocols during Days 180 and 360.  Int. J. Mol. Sci. 2012, 13  5670 
 
 
4.6. Statistical Analysis 
All  data  analyses  were  performed  using  SPSS  version  16.0  (SPSS,  Inc.,  Chicago  IL).  For 
comparisons between the groups, the chi square test, the Student’s t-test, the Mann-Whitney U test and 
the Wilcoxon rank sum tests were used, as appropriate.  
Because  some  data  were  missing  for  the  post-baseline  MRI  endpoints,  the  principle  of  “last 
observation carried forward” was used for the value. If no post-baseline value was available for a 
subject, then the mean value was calculated at the specified visit using all available data. The mean 
value was used as the imputed value. 
All 12 enrolled patients entered into the intention-to-treat (ITT) analysis. Patients who stopped the 
study drug were asked to remain in the study for the ITT analysis, but a covariate for the month of the 
drop-out was added. 
All p values were based on two-tailed tests and the minimum significant level was p < 0.05 and a 
trend p < 0.1.  
5. Conclusion 
GA may favorably affect early events in lesion formation, in addition to exerting more transient 
beneficial  effects  on  established  areas  of  inflammation  and  demyelination,  an  effect  that  may  be 
observed only with the 3 T optimized protocol and not the 1.5 T standard protocol. 
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